Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Nature Medicine

Volumn 22, Issue 11, 2016, Pages 1294-1302

  Frentzas, Sophia ^a,b   Simoneau, Eve ^c   Bridgeman, Victoria L ^a   Vermeulen, Peter B ^a,d   Foo, Shane ^a   Kostaras, Eleftherios ^a   Nathan, Mark R ^a   Wotherspoon, Andrew ^b   Gao, Zu Hua ^c   Shi, Yu ^c   Van Den Eynden, Gert ^d   Daley, Frances ^b   Peckitt, Clare ^b   Tan, Xianming ^e   Salman, Ayat ^c   Lazaris, Anthoula ^c   Gazinska, Patrycja ^f   Berg, Tracy J ^a   Eltahir, Zak ^b   Ritsma, Laila ^g   Van Rheenen, Jacco ^g   Khashper, Alla ^c   Brown, Gina ^b   Nyström, Hanna ^d,h   Sund, Malin ^h   Van Laere, Steven ^d   Loyer, Evelyne ⁱ   Dirix, Luc ^d   Cunningham, David ^b   Metrakos, Peter ^c   Reynolds, Andrew R ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d Gasthuiszusters Antwerpen Hospitals St Augustinus   (Belgium)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f GUY S HOSPITAL   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; BEVACIZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARPC3 PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL; BREAST CANCER; CANCER CELL; CELL INFILTRATION; CELL MOTILITY; COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; LIVER CELL; LIVER METASTASIS; LIVER PARENCHYMA; MORPHOLOGY; PRECLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; ADULT; AGED; BREAST TUMOR; CANCER GRADING; CARCINOMA; CELL MOTION; COLORECTAL NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE SILENCING; GENETICS; HT-29 CELL LINE; LIVER NEOPLASMS; LUNG CARCINOMA; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PAGET NIPPLE DISEASE; PATHOLOGY; SECONDARY; VASCULARIZATION; VERY ELDERLY;

ACTIN-RELATED PROTEIN 2-3 COMPLEX; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL MOVEMENT; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84991735476     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4197     Document Type: Article

References (78)

1. Ferrara, N., Hillan, K.J., Gerber, H.P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
2. Kerbel, R.S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
3. Hurwitz, H. et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
4. Cunningham, D. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 14, 1077-1085 (2013).
5. Ebos, J.M. & Kerbel, R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
6. Vasudev, N.S. & Reynolds, A.R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17, 471-494 (2014).
7. Pezzella, F. et al. Angiogenesis in primary lung cancer and lung secondaries. Eur. J. Cancer 32A, 2494-2500 (1996).
8. Vermeulen, P.B. et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J. Pathol. 195, 336-342 (2001).
9. Döme, B., Hendrix, M.J., Paku, S., Tóvári, J. & Tímár, J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am. J. Pathol. 170, 1-15 (2007).
10. Donnem, T. et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. 2, 427-436 (2013).
11. Jayson, G.C., Kerbel, R., Ellis, L.M. & Harris, A.L. Antiangiogenic therapy in oncology: current status and future directions. Lancet 388, 518-529 (2016).
12. Adams, R.B. et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15, 91-103 (2013).
13. Van den Eynden, G.G. et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 73, 2031-2043 (2013).
14. Stessels, F. et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br. J. Cancer 90, 1429-1436 (2004).
15. Gruenberger, B. et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J. Clin. Oncol. 26, 1830-1835 (2008).
16. Chaudhury, P. et al. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB 12, 37-42 (2010).
17. Wong, R. et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann. Oncol. 22, 2042-2048 (2011).
18. Chun, Y.S. et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. J. Am. Med. Assoc. 302, 2338-2344 (2009).
19. Shindoh, J. et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J. Clin. Oncol. 30, 4566-4572 (2012).
20. Boonsirikamchai, P. et al. CT fndings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am. J. Roentgenol. 197, W1060-W1066 (2011).
21. Van den Eynden, G.G. et al. The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin. Exp. Metastasis 29, 541-549 (2012).
22. Nürnberg, A., Kitzing, T. & Grosse, R. Nucleating actin for invasion. Nat. Rev. Cancer 11, 177-187 (2011).
23. Otsubo, T. et al. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Mod. Pathol. 17, 461-467 (2004).
24. Iwaya, K. et al. Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma. Cancer Sci. 98, 992-999 (2007).
25. Kopetz, S. et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 69, 3842-3849 (2009).
26. Nyati, M.K. et al. The potential of 5-fuorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther. 9, 844-849 (2002).
27. Gray, M.J. et al. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 27, 7192-7200 (2008).
28. Liang, W.C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).
29. Miller, K.D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792-799 (2005).
30. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
31. Miles, D.W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the frst-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239-3247 (2010).
32. Robert, N.J. et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for frst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260 (2011).
33. Brufsky, A.M. et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the effcacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 29, 4286-4293 (2011).
34. Naresh, K.N., Nerurkar, A.Y. & Borges, A.M. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology 38, 466-470 (2001).
35. Jeong, H.S. et al. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J. Natl. Cancer Inst. 107, djv155 (2015).
36. Colpaert, C.G. et al. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fbrin deposition. Histopathology 42, 530-540 (2003).
37. Breast Cancer Progression Working Party. Evidence for novel nonangiogenic pathway in breast-cancer metastasis. Lancet 355, 1787-1788 (2000).
38. Szabo, V. et al. Mechanism of tumour vascularization in experimental lung metastases. J. Pathol. 235, 384-396 (2015).
39. Carbonell, W.S., Ansorge, O., Sibson, N. & Muschel, R. The vascular basement membrane as "soil" in brain metastasis. PLoS One 4, e5857 (2009).
40. Bugyik, E. et al. Lack of angiogenesis in experimental brain metastases. J. Neuropathol. Exp. Neurol. 70, 979-991 (2011).
41. Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002-1016 (2014).
42. Jain, R.K. et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338 (2009).
43. Semelka, R.C., Hussain, S.M., Marcos, H.B. & Woosley, J.T. Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic fndings-initial observations. Radiology 215, 89-94 (2000).
44. Kuczynski, E.A. et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J. Natl. Cancer Inst. 108, djw030 (2016).
45. Rubenstein, J.L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306-314 (2000).
46. Küsters, B. et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 62, 341-345 (2002).
47. Leenders, W.P. et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10, 6222-6230 (2004).
48. Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
49. de Groot, J.F. et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncol. 12, 233-242 (2010).
50. Lu, K.V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35 (2012).
51. Sennino, B. et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2, 270-287 (2012).
52. Depner, C. et al. EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. Nat. Commun. 7, 12329 (2016).
53. Bland, J.M. & Altman, D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307-310 (1986).
54. Ribero, D. et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110, 2761-2767 (2007).
55. Chang, H.H., Leeper, W.R., Chan, G., Quan, D. & Driman, D.K. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am. J. Surg. Pathol. 36, 570-576 (2012).
56. Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206-2223 (2013).
57. Hammond, M.E. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, e48-e72 (2010).
58. Wolff, A.C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
59. Gourlaouen, M., Welti, J.C., Vasudev, N.S. & Reynolds, A.R. Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells. J. Biol. Chem. 288, 7467-7480 (2013).
60. Grambsch, P.M. & Therneau, T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515-526 (1994).
61. International Standards Organization. Technical Specification 25237. Health Informatics-Pseudonimization (International Standards Organization, 2008).
62. El Emam, K. & Arbuckle, L. Anonymizing Health Data (O'Reilly, Sebastopol, California, USA, 2014).
63. Council of the European Union. General Data Protection Regulation, first reading, 15039/15 (Brussels, 2015).
64. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Definitions for Genomic Biomarkers, Pharmacogenetics, Genomic Data and Sample Coding Categories. Efficiency Guideline E15 (2007). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E15/Step4/E15-Guideline.pdf
65. Revised Statutes of Alberta, as amended (Queen's Printer, 2000).
66. Information Commissioner's Office (UK). Anonymisation: Managing Data Protection Risk, Code of Practice (circa 2012). https://ico.org.uk/media/1061/anonymisation-code.pdf
67. Global Alliance for Genomics and Health. Privacy and Security Policy (2015). https://genomicsandhealth. org/work-products-demonstration-projects/privacy-and-security-policy
68. Global Alliance for Genomics & Health. Data Sharing Lexicon (2015). http://genomicsandhealth.org/work-products-demonstration-projects/data-sharing-lexicon
69. United States Code of Federal Regulations. Title 45: Public Welfare, Part 164: Security and Privacy. Office of the Federal Register, National Archives and Records Service, 1996
70. Homer, N. et al. PLoS Genet. 4, 1000167 (2008).
71. Lin, Z., Owen, A.B. & Altman, R.B. Science 305, 183 (2004).
72. Malin, B. & Sweeney, L. J. Biomed. Inform. 37, 179-192 (2004).
73. Schadt, E.E., Woo, S. & Hao, K. Nat. Genet. 44, 603-608 (2012).
74. Gymrek, M., McGuire, A.L., Golan, D., Halperin, E. & Erlich, Y. Science 339, 321-324 (2013).
75. Nietfeld, J.J. EMBO Rep. 8, 518 (2007).
76. Article 29 Working Party. Opinion 05/2014 on Anonymisation Techniques (2014). http://ec.europa. eu/justice/data-protection/article-29/documentation/opinion-recommendation/files/2014/wp216-en.pdf
77. Article 29 Working Party. Opinion 04/2007 on the Concept of Personal Data (2007). http://ec.europa. eu/justice/data-protection/article-29/documentation/opinion-recommendation/files/2007/wp136-en.pdf
78. Institute of Medicine. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health through Research (National Academies, Washington, DC, 2009).